The incidence of adverse events was 10.9 % in the 0.2 mg group ( dizziness 5.5 % ; abnormal ejaculation 1.8 % ; palpitation 1.8 % ; and headache 1.8 % ) and 9.09 % in the 0.4 mg group ( dizziness 3.6 % ; abnormal ejaculation 1.8 % ; palpitations 1.8 % ; and headache 1.8 % ) .